Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial of SRA-737 in combination with immuno-oncology agents

Trial Profile

A trial of SRA-737 in combination with immuno-oncology agents

Phase of Trial: Phase I/II

Latest Information Update: 17 May 2018

At a glance

  • Drugs SRA 737
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 May 2018 New trial record
    • 10 May 2018 According to a Sierra Oncology media release, the company is currently designing a clinical study evaluating SRA737 in combination with immuno-oncology agents, which potentially could be submitted to regulatory authorities in the fourth quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top